Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CMBI Recommends 3SBIO, Viewing Pharma Sector Pullback as Rebalancing of Industry Valuation & Performance
Recommend 17 Positive 29 Negative 8 |
||||
|
||||
|
In its research report, CMBI attributed the recent pharma sector pullback to the digestion and rebalancing of valuations and expectations, which will create a better investment window for future positioning. Looking ahead to 2026, as the trend of innovative drugs going overseas will continue in the long term, CMBI will focus on the clinical progress and data realization of the overseas pipeline as a core catalyst. In terms of industry outlook, CMBI said it will uphold a more conservative positioning strategy while pursuing opportunities in undervalued stocks. It recommended buying 3SBIO (01530.HK), GUSHENGTANG (02273.HK), WUXI XDC (02268.HK), and SINO BIOPHARM (01177.HK). CMBI's ratings and target prices for these stocks are available in a separate table. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
